Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 May;32(5):747–751. doi: 10.1128/aac.32.5.747

Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.

M Fernandez-Guerrero 1, M Rouse 1, N Henry 1, W Wilson 1
PMCID: PMC172264  PMID: 3164989

Abstract

Ciprofloxacin was more effective (P less than 0.01) than either imipenem or nafcillin therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis in rabbits after 2 or 3 days of treatment. There was no significant difference between results of treatment of methicillin-susceptible S. aureus experimental endocarditis with ciprofloxacin and results with the combination of nafcillin and gentamicin. Ciprofloxacin was more effective (P less than 0.01) than vancomycin therapy of experimental methicillin-resistant S. aureus endocarditis after 3 days of treatment. After 5 days of treatment, there was no significant difference between the results of treatment of experimental methicillin-resistant S. aureus endocarditis with ciprofloxacin and results with vancomycin.

Full text

PDF
747

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams B., Sklaver A., Hoffman T., Greenman R. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Ann Intern Med. 1979 May;90(5):789–791. doi: 10.7326/0003-4819-90-5-789. [DOI] [PubMed] [Google Scholar]
  2. Bayer A. S., Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis. 1985 Jan;151(1):157–165. doi: 10.1093/infdis/151.1.157. [DOI] [PubMed] [Google Scholar]
  3. Bayer A. S. Staphylococcal bacteremia and endocarditis: state of the art. Arch Intern Med. 1982 Jun;142(6):1169–1177. [PubMed] [Google Scholar]
  4. Carpenter T. C., Hackbarth C. J., Chambers H. F., Sande M. A. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1986 Sep;30(3):382–384. doi: 10.1128/aac.30.3.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chambers H. F., Korzeniowski O. M., Sande M. A. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. Medicine (Baltimore) 1983 May;62(3):170–177. [PubMed] [Google Scholar]
  6. Chin N. X., Neu H. C. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Mar;25(3):319–326. doi: 10.1128/aac.25.3.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Crump B., Wise R., Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother. 1983 Nov;24(5):784–786. doi: 10.1128/aac.24.5.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dickinson G., Rodriguez K., Arcey S., Alea A., Greenman R. Efficacy of imipenem/cilastatin in endocarditis. Am J Med. 1985 Jun 7;78(6A):117–121. doi: 10.1016/0002-9343(85)90113-5. [DOI] [PubMed] [Google Scholar]
  9. Eliopoulos G. M., Gardella A., Moellering R. C., Jr In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother. 1984 Mar;25(3):331–335. doi: 10.1128/aac.25.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fass R. J. In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother. 1983 Oct;24(4):568–574. doi: 10.1128/aac.24.4.568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Garrison P. K., Freedman L. R. Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart. Yale J Biol Med. 1970 Jun;42(6):394–410. [PMC free article] [PubMed] [Google Scholar]
  12. Kaatz G. W., Barriere S. L., Schaberg D. R., Fekety R. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1987 Apr;31(4):527–530. doi: 10.1128/aac.31.4.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. King A., Shannon K., Phillips I. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid. J Antimicrob Chemother. 1984 Apr;13(4):325–331. doi: 10.1093/jac/13.4.325. [DOI] [PubMed] [Google Scholar]
  14. Korzeniowski O., Sande M. A. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med. 1982 Oct;97(4):496–503. doi: 10.7326/0003-4819-97-4-496. [DOI] [PubMed] [Google Scholar]
  15. Levine D. P., Cushing R. D., Jui J., Brown W. J. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med. 1982 Sep;97(3):330–338. doi: 10.7326/0003-4819-97-3-330. [DOI] [PubMed] [Google Scholar]
  16. Moorhouse E. C., Mulvihill T. E., Jones L., Mooney D., Falkiner F. R., Keane C. T. The in-vitro activity of some antimicrobial agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1985 Mar;15(3):291–295. doi: 10.1093/jac/15.3.291. [DOI] [PubMed] [Google Scholar]
  17. Reeves D. S., Bywater M. J., Holt H. A., White L. O. In-vitro studies with ciprofloxacin, a new 4-quinolone compound. J Antimicrob Chemother. 1984 Apr;13(4):333–346. doi: 10.1093/jac/13.4.333. [DOI] [PubMed] [Google Scholar]
  18. Sande M. A., Johnson M. L. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis. 1975 Apr;131(4):367–375. doi: 10.1093/infdis/131.4.367. [DOI] [PubMed] [Google Scholar]
  19. Scheld W. M., Keeley J. M. Imipenem therapy of experimental Staphylococcus aureus and Streptococcus faecalis endocarditis. J Antimicrob Chemother. 1983 Dec;12 (Suppl 500):65–78. doi: 10.1093/jac/12.suppl_d.65. [DOI] [PubMed] [Google Scholar]
  20. Sorrell T. C., Packham D. R., Shanker S., Foldes M., Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):344–350. doi: 10.7326/0003-4819-97-3-344. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES